R wave amplitude in the aVL lead was significantly higher in hypertensive patients with urgencies compared to those without urgencies and healthy subjects (0.76 vs 0.49 vs 0.22 mV; p<0.001).
Cross-Sectional (n=339)
Yes
Does R wave amplitude in the aVL lead correlate with cardiovascular risk and hypertensive urgencies in patients with arterial hypertension?
RaVL > 0.40 mV may serve as a useful ECG marker for cardiovascular risk stratification and detection of hypertension-mediated target organ damage.
Absolute Event Rate: 0.76% vs 0.22%
p-value: p=<0.001
Background: R wave amplitude in the aVL ECG lead (RaVL) has been identified as a marker of cardiovascular (CV) risk, hypertension-mediated target organ damage (HMOD), and mortality in patients with arterial hypertension (AH), where RaVL > 1.1 mV suggests left ventricular hypertrophy. However, the exact threshold for identifying high-risk patients has yet to be determined. Therefore, we compared RaVL values among hypertensive patients with and without hypertensive urgencies (HUs) and healthy subjects, aiming to identify the predictors of elevated RaVL and to compare its prognostic value with the SCORE 2 model. Methods: This cross-sectional study included 339 participants divided into three groups according to ambulatory blood pressure monitoring results: 100 patients with AH and HU from the emergency department, 134 patients with AH without HU, and 105 healthy subjects recruited from four family medicine practices. Basic laboratory parameters were determined, SCORE 2 risk was calculated, PWV was measured using oscillometry, and a standard 12-lead ECG was recorded in all participants. Results: Participants with AH and HU had the highest RaVL values compared to those with AH without HU and healthy subjects (averages of 0.76 ± 0.24 mV, 0.49 ± 0.27, 0.22 ± 0.25, respectively; p 0.40 mV had high CV risk (sensitivity of 58.16%, specificity of 73.68%; p < 0.001). Conclusions: In this study, RaVL demonstrated good prognostic value for CV risk stratification. However, larger studies are needed to determine a precise high-risk threshold to improve CV risk estimation and HMOD detection in patients with marginal SCORE 2 CV risk.
Jug et al. (Thu,) conducted a cross-sectional in Arterial hypertension (n=339). R wave amplitude in aVL lead (RaVL) vs. Healthy subjects and SCORE 2 model was evaluated on RaVL values across groups (AH with HU, AH without HU, healthy subjects) (p=<0.001). R wave amplitude in the aVL lead was significantly higher in hypertensive patients with urgencies compared to those without urgencies and healthy subjects (0.76 vs 0.49 vs 0.22 mV; p<0.001).